AbbVie buys $2.1bn Capstan, adding new in vivo CAR-T to pipeline

AbbVie has agreed to acquire Capstan Therapeutics for up to $2.1bn, adding a “high-risk, high-reward” clinical-stage in vivo CAR-T candidate to its pipeline. Capstan is developing a new type of CAR-T therapy that overcomes limitations with current options. Currently approved therapies of this kind…